Agensys - Top 20 VC deals of 2007

Company: Agensys
Based: Santa Monica, CA
Amount: $41.31
Round: Fourth
Investors: Alta Partners, Bear Stearns Health Innoventures, Fukui JAFCO Company, HBM BioVentures, Lombard Odier Darier Hentsch, Nextech Venture, OrbiMed Advisors, Undisclosed Investor, Undisclosed Venture Firm

Scoop: Agensys is developing fully-human monoclonal antibodies (MAbs) to treat solid tumor cancers. The funding is being used to advance the company's prostate cancer program through Phase II and bring three more products into clinical development by the end of 2008. In November 2007, Japan's Astellas bought Agensys for $387 million plus up to $150 million more in milestones. Antibodies will likely play an ever-growing role in cancer treatments, and are expected to command a $32 billion market by 2015.

More News:
Astellas inks $537M deal for Agensys. Report
Agensys gains $41M in venture funds. Report

Agensys - Top 20 VC deals of 2007

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.